Bacteremia due to Methicillin-Resistant Staphylococcus aureus New Therapeutic Approaches INFECTIOUS DISEASE CLINICS OF NORTH AMERICA Holubar, M., Meng, L., Deresinski, S. 2016; 30 (2): 491-?


This article reviews recent clinical evidence for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Vancomycin remains the initial antibiotic of choice for the treatment of patients with MRSA bacteremia and endocarditis due to isolates with vancomycin minimum inhibitory concentration =2 µg/mL, whereas daptomycin is an effective alternative, and ceftaroline seems promising. Treatment options for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains include daptomycin, ceftaroline, and combination therapies. There is a critical need for high-level evidence from clinical trials to allow optimally informed decisions in the treatment of MRSA bacteremia and endocarditis.

View details for DOI 10.1016/j.idc.2016.02.009

View details for Web of Science ID 000378466900010

View details for PubMedID 27208769